For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

AICAR (acadesine): origin, structure and research history

Research Library › Mitochondrial & Coenzyme

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also called acadesine or AICA riboside) is a synthetic nucleoside, not a peptide. In the early 1990s the company Gensia developed it as an adenosine-regulating drug candidate for heart surgery. After a 1995 paper by Corton, Hardie and colleagues, it became widely used in laboratories as an activator of AMP-activated protein kinase (AMPK). As of 23 Oct 2026 it has never been approved by the FDA, and it is on the WADA Prohibited List.

Key facts

TypeNucleoside (imidazole ribonucleoside); not a peptide
Chemical name5-amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide (CAS 2627-69-2; C9H14N4O5; MW 258.2)
Other namesAcadesine, AICA riboside, NSC 105823; Gensia brand name Arasine
Pharmaceutical developerGensia (NDA filed December 1992; not approved)
Laboratory use described1995, Corton, Gillespie, Hawley and Hardie, European Journal of Biochemistry
Designed / proposed targetAdenosine regulation in ischemic heart tissue (Gensia); AMPK activation in intact cells (laboratory use)
Regulatory status (Oct 2026)Not FDA-approved; not on FDA compounding nomination lists; WADA-prohibited (S4, AMPK activators)

Who developed it

Acadesine was taken into clinical development by the biotechnology company Gensia, which called its product Arasine. By early 1993 Gensia had filed a U.S. new drug application (December 1992) and a European registration (January 1993). Dennis Mangano of the University of California, San Francisco, presented the company’s main Phase III study in March 1993 [3]. An earlier multicenter randomized study in coronary bypass surgery was published by Leung, Mangano and the SPI Research Group in 1994 [4].

AICAR’s second identity, as a laboratory tool, came from biochemistry. In 1995, J.M. Corton, J.G. Gillespie, S.A. Hawley and D.G. Hardie asked in the European Journal of Biochemistry whether the compound offered a specific way to activate AMP-activated protein kinase in intact cells [2]. That paper is the usual starting point for AICAR’s long use in AMPK research.

What it was designed to target

Gensia described acadesine as an adenosine-regulating agent. It was proposed to raise local adenosine levels in heart tissue during periods of reduced blood flow [3, 5].

In cell biology, AICAR is used for a different purpose: as a cell-permeable compound that activates AMPK, the enzyme complex that senses a cell’s AMP-to-ATP balance [1, 2].

Why it was created

Acadesine was originally investigated in a research program on protecting heart muscle during coronary artery bypass graft (CABG) surgery, where interrupted blood flow is unavoidable [3, 4]. Gensia’s 1992 application did not lead to FDA approval [3, 6]. Years later, a large international trial, RED-CABG, revisited acadesine in high-risk bypass patients. It was stopped early for futility, and the results were published in JAMA in 2012 [5]. No acadesine product has been approved in the United States [6].

Research timeline

  • Dec 1992: Gensia files a U.S. new drug application for acadesine (Arasine) [3].
  • Mar 1993: Phase III bypass-surgery results presented at the American College of Cardiology meeting [3].
  • 1994: First multicenter randomized acadesine study in CABG published in Anesthesia & Analgesia [4].
  • 1995: Corton, Hardie and colleagues describe AICAR as a way to activate AMPK in intact cells [2].
  • 2012: RED-CABG trial, stopped early for futility, published in JAMA [5].

Regulatory status as of October 2026

As of 23 Oct 2026, AICAR/acadesine is not approved by the FDA, and Drugs@FDA lists no acadesine product [6]. It does not appear on FDA’s 503A bulk-substance nomination list (updated 14 May 2026) [7], the 503B nomination list [8], or the Category 2 list of substances that may present significant safety risks [9]. It was not on the 2026 agendas of FDA’s Pharmacy Compounding Advisory Committee [10].

The World Anti-Doping Agency’s 2026 Prohibited List names AICAR as an example of activators of AMP-activated protein kinase, under S4 hormone and metabolic modulators [11].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Is AICAR a peptide?

No. AICAR is a nucleoside, made of an imidazole carboxamide base attached to the sugar ribose. It is often sold by peptide suppliers but is chemically unrelated to peptides.

What is acadesine?

Acadesine is the nonproprietary name for AICAR. Gensia developed it under the brand name Arasine as a drug candidate for heart surgery in the early 1990s.

Is AICAR FDA approved?

No. Gensia’s 1992 application was not approved, a later Phase III trial (RED-CABG) was stopped for futility, and as of 23 Oct 2026 no acadesine product is FDA-approved.

Is AICAR on the WADA prohibited list?

Yes. The 2026 WADA Prohibited List names AICAR as an example of AMPK activators in section S4.

Sources

  1. Cayman Chemical. AICAR (acadesine; AICA-riboside), item 10010241: chemical identity (CAS 2627-69-2, C9H14N4O5, FW 258.2). Link
  2. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229:558-565. Link
  3. The Pink Sheet. Gensia Arasine study secondary analysis shows heart attack decrease. 22 Mar 1993. Link
  4. Leung JM, Stanley T, Mathew J, et al.; SPI Research Group. An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. Anesth Analg. 1994;78(3):420-434. doi:10.1213/00000539-199403000-00002 Link
  5. Newman MF, Ferguson TB, White JA, et al.; RED-CABG Steering Committee and Investigators. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA. 2012;308:157-164. (Summary: American College of Cardiology.) Link
  6. U.S. Food and Drug Administration. Drugs@FDA, browse by letter A (no acadesine entry). Link
  7. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated 14 May 2026). Link
  8. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the FD&C Act (updated 21 Mar 2025). Link
  9. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 Apr 2026). Link
  10. Latham & Watkins. FDA on Peptides: A New Landscape for Compounders (2026), summarizing 91 Fed. Reg. 20465 (16 Apr 2026) and the PCAC meeting agendas. Link
  11. World Anti-Doping Agency. 2026 Prohibited List, as published in the Dutch Treaty Series (Tractatenblad 2026, 25), section S4.4.1. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top